Three other patient charities have settled similar cases since last October, when federal authorities accused drugmakers and patient charities of creating programs to favor some drugs over lower-cost options to boost profits.
The U.S. Justice Department said the fourth charity, called Patient Services, created a fund for patients with a disease called homozygous familial hypercholesterolemia after being asked to do so by Aegerion Pharmaceuticals, STAT reported. The fund was only supported by Aegerion and allowed the drugmaker to boost its sales.
The Patient Services case differs from the other three because the charity filed a lawsuit in 2018 accusing the government of inhibiting its free speech rights by limiting the information it was allowed to provide to donors.
Read the full article here.
More articles on pharmacy:
BCBS, Civica Rx create subsidiary to cut generic drug costs
PhRMA spent a record $29M on lobbying in 2019
Former Insys CEO gets 30 months in prison
